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Aztreonam is a monocyclic synthetic antimicrobial with bactericidal activity against Gram-negative bacteria, the first 
agent from the monobactam family to be therapeutically approved. It was developed and validated analytical method 
using high performance liquid chromatography with UV detection at 292 nm to quantify the aztreonam. Furthermore, 
assessing stability through stress tests was carried out. The chromatographic separation was carried out by reverse phase 
on an Agilent C18 column (250 x 4.6 mm, 5 µm) with a mobile phase composed of water:ethanol (70:30, v/v) adjusted to 
pH 2.5 with acetic acid, pumped isocratically at a flow rate of 0.5 mL.min
-1
. The validation parameters linearity, 
selectivity, precision, accuracy, robustness, limits of detection and quantification were determined. The method proposed 
provides linear response within the concentration range of 45-95 µg.mL
-1
 for aztreonam. Results obtained were found to 
be satisfactory. The proposed method is linear, accurate, precise, selective, and robust being able to quantify the 
aztreonam in pharmaceutical preparations. The validated method was suitable for applications in quality control 
laboratories. 
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Introduction 
Aztreonam (Figure 1), chemically named 2-[[[1-(2-
amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1sulfo-3-
azetidinyl)amino]-2-oxoethylidene]amino]oxy]2-
methyl, is an antibiotic belonging to the monocyclic 
monobactam family (1-3). Nowadays, it is used to treat 
infections caused by Gram-negative bacteria. It is 
active against Escherichia coli, Klebsiella spp., Proteus 
spp., Serratia marcescens, Salmonella spp, 
Enterobacter spp., Pseudomonas aeruginosa, 
Haemophilus influenzae and Neisseria meningitides (4-
6). It is, however, ineffective against Gram-positive 
and anaerobic pathogens (7,8). It is indicated in cases 
of urinary tract infections, skin infections and intra-
abdominal infections (9). This antimicrobial agent is 
not absorbed from the gastrointestinal tract and 
therefore can be used only by parenteral route (10). 
After intramuscular administration, peak serum 
concentrations are reached within one hour (11). 
Regarding the mechanism of action, aztreonam inhibits 
cell wall biosynthesis in Gram-negative bacteria by 
binding to proteins, which causes cell lysis (12).
 
Several methods are described for the quantitative 
determination of aztreonam in pharmaceutical 
preparations, as a raw material or biological material. 
Some published papers bring HPLC analysis for 
aztreonam (13-16), but they use toxic solvents. The 
aim of this study is to optimize the system, improve the 
constitution of the mobile phase, decrease analysis 
time, use less toxic reagents and mainly the offspring 
less residue. In this context, the objective of this study 
is to develop and validate an analytical method using a 
cheap, simple and helpful mobile phase to quantify 
aztreonam. Furthermore, assessing stability through 
stress tests to improve quality control and ensure 
effective therapy (17,18).
 
 
Figure 1 Chemical structure of aztreonam (CAS: 78110-38-
0)(12). 
 
Experimental 
Chemicals 
Aztreonam reference substance (RS) (purity 
99.2%), lot number 0908120, were kindly donated by 
União Química Pharmaceutical Industry (Pouso 
Alegre, Brazil). Batches of Uni-Aztrenam™ 
lyophilized powder, containing 1 g aztreonam were 
obtained from commercial sources within its shelf-life. 
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The adjuvant present and tested was L-arginine. 
Ethanol and acetic acid were obtained from Tedia 
(Darmstadt, Germany). The water was obtained by a 
Milli-Q system (Millipore, Milford, USA). The 
solutions were filtered through a hydrophilic Millipore 
filtration membrane (13-mm, 0.45-mm pore size). 
 
Equipments and chromatographic conditions 
The liquid chromatographic system used consisted 
of a Waters chromatograph equipped with Waters 1525 
pump binary grade, Rheodyne Breeze-7725i injection 
valve with 20 µL loop, UV-Vis Waters 2487 detector 
and reserved phase Agilent C18 column (250x4.6 mm 
i.d., 5 mm particle size) and a Waters C18 column 
(250x4.6 mm i.d., 5 mm particle size) to achieve 
robustness. The analyses were performed at room 
temperature under isocratic conditions with a flow rate 
of 0.5 mL.min
-1
. The mobile phase, consisted of 
water:ethanol (70:30) adjusted to pH 2.5 with acetic 
acid, was vacuum filtered and degassed under 
ultrasonic liquid (Model XL 2020) for 30 minutes. 
Aztreonam solution, prepared in mobile phase at a 
concentration of 200 µg.mL
-1
, was filtered on 0.45 µm 
hydrophilic membrane. The injection volume was 20 
µL. UV detection of the analyte was carried out at 292 
nm. 
 
Preparation of solutions 
The stock and sample (a pool of 20 batches with an 
average weight of 1.6861 g) solutions were prepared by 
accurately weighing 20 mg of aztreonam RS, 
transferring to a 100 mL volumetric flask and dissolved 
in mobile phase to give a concentration of 200 µg.mL
-1
. 
Appropriate dilutions of the stock solution were 
transferred to 10 mL volumetric flasks, and volume 
was completed with mobile phase. The solutions were 
filtered through membranes of 0.45 µm x 13-mm. 
 
Degradation conditions 
Since stability testing is an important part of the 
process of drug product development, a forced 
degradation study was carried by exposing the drug to 
acidic, alkaline, neutral, oxidative and photolytic 
conditions (19,20). Forced degradation studies were 
performed to evaluate the stability indicating properties 
and specificity of the method (17). 
 
Preparation of sample solution 
Acidic, alkaline and neutral degradation studies 
Acid degradation was carried out in 0.1 M HCl 
(Synth, Brazil) at a concentration of 75 µg.mL
-1
 
aztreonam for 48 hours. Stress studies in basic 
conditions were conducted using a drug concentration 
of 75 µg.mL
-1
 in 0.01 M NaOH (Synth, Brazil) for 168 
hours. These solutions were exposed to a temperature 
of 60 ºC. Additionally, the aztreonam in mobile phase 
at a concentration of 75 µg.mL
-1
 was heated at 60 ºC 
for 168 hours. 
 
Oxidative degradation 
Oxidative degradation carried out in H2O2 3% 
(Vetec Química, Brazil) at a concentration of 75 
µg.mL
-1
 aztreonam. These solutions were exposed to a 
temperature of 60ºC for 1 hour. 
 
Photostability 
Aztreonam was exposed the photolytic degradation 
using a mirrored chamber with UV C light for 168 
hours in a concentration of 75 µg.mL
-1
. 
 
System suitability 
System Suitability tests are an integral part of a 
liquid chromatographic method, and they were used to 
verify that the proposed method was able to produce 
good resolution with high reproducibility (2). The 
system suitability was determined by six replicate 
injections from prepared standard solutions and 
analyzing the peak area, theoretical plates (N) and 
tailing factors (T). 
 
Method validation 
The validation parameters for linearity, specificity, 
precision, accuracy, robustness, limit of detection 
(LOD) and limit of quantification (LOQ) was 
according to the parameters established in guidelines 
(17,18,22-28). 
 
Linearity 
Linearity test solutions for the assay method were 
prepared from a stock solution at six concentrations of 
45, 55, 65, 75, 85, 95 μg.mL-1. The analytical curve 
was evaluated on three different days. Each 
concentration was determined in triplicate. Linearity 
was analyzed with least squares linear regression, 
fitting the data using the least squares method. 
 
Specificity 
Specificity was established by analyzing the 
excipient (L-arginine) present in the samples 
aztreonam, evaluated by regression analysis in six 
concentrations ranging from 45 to 95 µg.mL
-1
 prepared 
on three consecutive days. Each concentration was 
determined in triplicate. The specificity was also 
assessed following the chromatograms of solutions of 
excipient, aztreonam sample and RS at a concentration 
of 200 µg.mL
-1
 and the stress test. The excipient 
solution was prepared under the same conditions as the 
commercial samples. The specificity of the developed 
HPLC method for aztreonam was carried out in the 
presence of its degradation products. Intentional 
degradation was attempted to stress conditions 
exposing to evaluate the ability of the proposed method 
to separate aztreonam from its degradation products. 
 
Precision 
To study the precision, it was used the 
concentration of 45 μg.mL-1 of aztreonam (test 
concentration). Precision was evaluated with respect to 
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repeatability and intermediate precision. Repeatability 
was assessed by analysis of standard solutions of 
aztreonam in the same concentration and the same day, 
performing seven repetitions. Intermediate precision 
was studied by performing the analysis on three 
different days (inter-day) and by another analyst in the 
same laboratory under the same experimental 
conditions (between-analysts). Data from the relative 
standard deviation (RSD) were evaluated. 
 
Accuracy 
The accuracy of the method was determined by 
recovering the standard solution and sample in 
triplicate on three levels 80, 100 and 120% 
concentration method (45 µg.mL
-1
), in accordance with 
the ICH recommendations.
17
 In 10 mL volumetric 
flasks, aliquots of 0.3, 0.95 and 1.4 mL of this solution 
(concentrations 36, 45 and 54 µg.mL
-1
, respectively) 
were each added to 1.3 mL solutions of sample. The 
recoveries of aztreonam for testing and relative 
standard deviation (RSD) were determined. 
 
Robustness 
To evaluate robustness of the method, it was used 
aztreonam concentration of 45 μg.mL-1 (concentration 
test). The robustness of the method was verified by the 
variation in wavelength (292 nm normal, 290 and 294 
nm changed), temperature (26°C normal, 18°C 
changed), column (Waters normal, Agilent changed), 
flow (0.50 mL.min
-1
 normal, 0.48 and 0.52 mL.min
-1
 
changed), volume of injection (20 µL normal, 18 and 
22 µL changed), ethanol supplier (Tedia normal, 
J.T.Baker changed) and preparation of solution in 
mobile phase (normal) and water (changed). 
 
Limits of detection and quantitation 
The limit of detection (LOD) and the limit of 
quantitation (LOQ) of the method were obtained from 
equations (1) and (2), 
 
LOD =
3.3 𝜎
SD
                   Eq. 1 
 
LOQ =
10 𝜎
SD
                         Eq. 2 
 
where S.D. is the intersection standard deviation and α 
is the average slope, obtained from the analytical 
curves of the linearity study. 
 
Results and Discussion 
Method development 
The methods described in the literature for the 
determination of aztreonam are time consuming, 
complex, use toxic solvents and require the use of large 
amounts of organic solvents and high cost. In this 
paper, the selection of the mobile phase was based on 
peak parameters (height, tail symmetry, and tailings), 
analysis time, ease of preparation of the mobile phase 
and sample solvent, and costs less toxic. Furthermore, 
the mobile phase composition is simple and the column 
gave longer life and reduced risk of precipitations 
associated with the use buffers. The peak retention time 
was 5.9 minutes (Figure 2). This is a good value for a 
routine procedure in quality control and possible to 
analyze large numbers of samples on the same day.  
 
Figure 2 Chromatogram of standard (black), pharmaceutical 
product (blue) and excipient (green). 
 
Stress degradation experiments 
Stability testing is an important part of the process 
of drug product development. The purpose of stability 
testing is to provide evidence of how the quality of a 
drug substance or drug product varies with time under 
a variety of environmental conditions (19). The forced 
degradation studies provide information about the 
conditions in which the drug is unstable so that 
measures can be taken during manufacturing to avoid 
potential instabilities. The stability indicating 
capability of the method was established from the peak 
purity of aztreonam in degraded samples. The peak 
purity index and threshold for aztreonam in all cases 
was more than 0.99 (Table 1). Typical chromatograms 
obtained following the assay of stressed samples are 
shown in Figure 3.  
 
Table 1 Summary of forced degradation conditions for 
aztreonam quantitation by HPLC method. 
 
Stress conditions Time (hours) 
 
Degradation (%) 
Acid hydrolysis 
(0.1 M HCl) 
 
48 
 
14.86 
Alkaline hydrolysis 
(0.01 M NaOH) 
168 
 
0.82 
Photostability 168 
 
1.53 
Oxidation  
(3% H2O2) 
1* 
 
18.02 
Neutral (60ºC) 168 
 
19.04 
*hour 
 
Aztreonam has deteriorated rapidly in oxidative 
degradation, the main peak lost 18.02% of area after 1 
hour. In acidic conditions, aztreonam 14.86% degraded 
after 48 hours and neutral at 60°C, 19.04% after 168 
hours. 
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Figure 3 Chromatograms of aztreonam sample after (A) 
oxidative degradation (H202 3% for 1 hour), (B) acid 
degradation (HCl 0.1 M, for 48 h at 60oC), (C) alkaline 
degradation (NaOH 0.01 M, for 168 hours at 60°C), (D) 
neutral degradation (mobile phase, for 168 hours at 60°C), 
(E) photolytic degradation (UV C light for 168 hours at 
25°C). 
 
Method Validation 
Linearity 
The analytical curves, resulting in from three 
consecutive days were fitted by linear regression 
analysis, whose straight line equation is: y = 
23817.3810x+1342.5926. The coefficient correlation 
was 0.9999 (Figure 4). Furthermore, data was validated 
by an analysis of variance (ANOVA), which showed 
highly significant regression, since the F values 
calculated were smaller than those F critical values 
(Table 2). 
 
Figure 4 Calibration curve constructed for aztreonam 
standard solutions in the range of 45 to 95 µg mL-1. 
 
Specificity 
Data from the calibration curve resulting from the 
average of three sample curves generated on three 
consecutive days, whose straight line equation is: y = 
22048.3038x + 22341.0111. The correlation coefficient 
was 0.9998. The data were validated by analysis of 
variance, and F calculated values were lower than the F 
critical values (Table 3).Moreover, specificity was 
demonstrated by the absence of any interfering peak in 
the chromatogram obtained, showing that the carrier 
does not interfere with the peak of aztreonam (Figure 
2). The specificity was also confirmed by studies of 
stress. 
 
 
Table 2 Analysis of variance (ANOVA) of peak’s area 
determined in the obtaining of the calibration curve of 
aztreonam using HPLC method. 
 
 
Table 3 Analysis of variance (ANOVA) of peak’s area 
determined in the obtaining of the calibration curve of 
aztreonam using HLPC method. 
 
Source of 
variation 
D
F 
Sum of 
square 
 
Variability 
 
F 
calculated 
 
F 
critical 
Between 
concentration 
5 27348154 54696309142 817.59* 3.11 
Linear 
regression 
1 27348154 27348154571 4087.96* 4.75 
Deviation of 
linearity 
4 0.00003 0.0000075 0.00 3.26 
Residue 12 80279202 66899335764 - - 
Total 17 274284337 - - - 
 
Precision 
Precision was evaluated with respect to 
repeatability and intermediate precision. Repeatability 
was determined by calculating the relative standard 
deviation (RSD) for seven repetitions of the test 
concentration (75 μg.mL-1) on the same day and under 
the same experimental conditions. The RSD value 
obtained was 0.55%. The intermediate precision was 
evaluated by calculating the recovery of the drug, 
performed on three different days (inter-day precision). 
The RSD value obtained was 0.31%. Finally, the 
between-analysts precision shows RSD = 1.31%. 
Values lower than 5% confirm the method is precise. 
The interday precision was evaluated by analysis of 
variance while the between-analyst precision was 
evaluated by Student's t test, as shown in Tables 4 and 
5. 
 
Source of 
variation 
DF 
 
Sum of 
square 
 
Variability 
 
F 
calculated 
 
F 
critical 
Between 
concentration 
5 297857 595714219 361.04* 3.11 
Linear 
regression 
1 297857 297857109 1805.21* 4.75 
Deviation of 
linearity 
4 0.00003 0.0000075 0.10 3.26 
Residue 12 197998 164998898 - - 
Total 17 299837 - - - 
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Table 4 Analysis of variance (ANOVA) for interday 
precision using HPLC method for determination of 
aztreonam. 
 
Source 
of 
variation 
DF 
Sum of 
square 
 
Average 
squares 
 
F 
calculated 
 
F 
critical 
Between 
groups 
2 873946361.3 4369731 7.04 9.55 
Within 
groups 
3 186149292 6204976 - - 
Total 5 1060095653 - - - 
 
Table 5 Student's t test for precision between analysts by 
HPLC method for analysis of aztreonam. 
 
Source of 
variation 
Average Degree of 
freedom 
Variance t 
calculated 
t 
critical 
Analyst 1 1754654.571 7 10268502 -0.58 2.17 
Analyst 2 1757528 7 64371204   
 
 
Accuracy 
The accuracy of the method was confirmed by 
determining the average recoveries of samples using 
the standard addition method. As shown in Table 5, the 
percentage recovery was 100.57%, with a standard 
deviation was of 0.21%. The results demonstrate that 
slight variations in the concentration of aztreonam can 
be readily quantified by the method as well as no 
interference of excipients therefore the analytical 
method developed is sufficiently accurate. 
 
Table 6 Determination of the accuracy of the analytical 
method for the analysis of aztreonam by HPLC. 
 
Robustness 
The robustness was found to be reliable, as 
determined by the RSD (<5%). We observed the 
constancy of peak area with change in the experimental 
parameters wavelength, temperature, column, flow, 
injection volume, ethanol supplier and sample 
preparation in water and mobile phase (Table 7). Small 
changes that occurred during the analysis did not affect 
the peak’s area of the samples. 
 
Table 7 Robustness test for aztreonam by HPLC method. 
Parameters (Normal – Changed) RSD (%) 
Wavelength (292 nm – 290/294 nm) 0.11 
Temperature (26 °C – 18 °C) 0.23 
Column (Waters – Agilent) 0.37 
Flow rate (0.50 mL/min – 0.48/0.52 mL/min) 0.24 
Injection volume (20 µL – 18/22 µL) 0.20 
Solvent supplier (Tedia – J.T.Baker) 0.07 
Sample preparation (mobile phase – water) 0.83 
RSD = relative standard deviation 
Limits of detection (LOD) and quantitation (LOQ) 
LOD and LOQ values were found to be 0.48 
μg.mL-1 and 1.46 μg.mL-1, respectively. The method is 
sensitive to small concentrations. 
 
System suitability 
System suitability tests are used to verify that the 
resolution and reproducibility were adequate for the 
analysis performed. The parameters measured were 
tailing factor, capacity factor, theoretical plates, 
retention time (5.013 min, RSD 0.61%) and 
repeatability as %RSD (0.47%) of peak area for six 
injections of a standard solution of aztreonam (100% 
concentration). The tailing factor showed less than 2 
(0.5, RSD 0.0%), the capacity factor was more than 1.5 
(2.25, RSD 0.89%) and the theoretical plates were 
more than 2000 (3475, RSD 0.87%). 
 
Green Chemistry 
The concept Green Chemistry has had a growing 
importance in the last decade and it is stimulated by the 
academy, industry segment and society. For this reason 
a new method was developed which uses a green 
mobile phase composed by water and ethanol to 
quantify aztreonam in pharmaceutical dosage forms. 
This mobile phase contributes to the environment, not 
only to waste parameter but also to operator. Moreover, 
these both solvents have a low price, and they could 
quantify aztreonam in a short time. Each analytical 
method can be characterized by its specific 
requirements. Therefore, it is very important to 
evaluate and to optimize the greenness of an analytical 
method or procedure and to focus on its least green 
aspect (29-31). 
The rapid analysis of aztreonam has been 
particularly of interest by pharmaceutical industries 
and quality control laboratories. In this aspect, it is 
possible to reduce residues, make a faster and cheaper 
analysis, and it is not time consuming. 
Despite the characteristic points of each analytical 
method and drugs or other substances determined, 
sample as well operator take an important role in every 
analysis. Moreover, the methods can also require the 
use of equipment, reagent and produce analytical 
residues. Although pharmaceutical analysis is a process 
comprising several steps influencing each other, 
Gałuszka and coworkers suggested six critical issues 
for Green Chemistry principles (28).
 
Solvents as ethanol and water were not frequently 
used as mobile phase in chromatographic system some 
years ago because the use of ethanol increased the 
working pressure due to it incorporates a higher 
viscosity to the system. However, nowadays modern 
instrumentation makes possible the use of ethanol as 
mobile phase solvent, as these devices support much 
higher pressures (32). Recently there are many 
researches published which could demonstrated that 
ethanol or methanol and water mixtures have excellent 
properties when used in chromatographic system of 
reverse phase C8 and C18 columns (32-41). Finally, 
Sample  
200 µg. mL-1 
RS concentration 
(µg.mL-1) 
Recovery 
(%) 
RSD 
(%) 
Mean 
recovery (%) 
Added Found  
 60 58.98 98.3 0.50  
 75 74.14 98.8 0.87 98.56 
 90 88.80 98.6 1.23  
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many analytical methods for quantitative determination 
of aztreonam in pharmaceutical products are described 
in the literature (13-16,42,43). Nevertheless, this 
research validates a new useful HPLC method, which 
shows the important characteristics such as 
environmentally healthy with green solvents and low 
residues amount. 
 
Conclusions 
The chromatographic method was successfully 
validated for quantitative determination of aztreonam. 
This method has advantages over other existing 
methods that are simplicity, speed, precision, accuracy 
and low cost. The main advantage of this method was 
the use of a mobile phase of very simple composition, 
which gave the column longer lifetime, and reducing 
risk of rainfall associated with the use of buffers in the 
solvent system. All validation parameters were found 
to be highly satisfactory, including linearity, 
selectivity, precision, accuracy, robustness and limit of 
detection and quantification appropriate. Furthermore, 
there was no interference from any components of 
pharmaceutical products or degradation. The method 
can therefore easily be applied in quality control 
laboratories providing new perspectives for process 
control. 
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